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MAIT cells: new guardians of the liver
This article was originally published under a CC BY-NC-ND 4.0 license, but has now been made available
under a CC BY 4.0 license.
Ayako Kurioka1, Lucy J Walker2, Paul Klenerman1,3 and Christian B Willberg1,3
The liver is an important immunological organ that remains sterile and tolerogenic in homeostasis, despite continual exposure to
non-self food and microbial-derived products from the gut. However, where intestinal mucosal defenses are breached or in the
presence of a systemic infection, the liver acts as a second 'firewall', because of its enrichment with innate effector cells able to
rapidly respond to infections or tissue dysregulation. One of the largest populations of T cells within the human liver are
mucosal-associated invariant T (MAIT) cells, a novel innate-like T-cell population that can recognize a highly conserved antigen
derived from the microbial riboflavin synthesis pathway. MAIT cells are emerging as significant players in the human immune
system, associated with an increasing number of clinical diseases of bacterial, viral, autoimmune and cancerous origin. As
reviewed here, we are only beginning to investigate the potential role of this dominant T-cell subset in the liver, but the reactivity
of MAIT cells to both inflammatory cytokines and riboflavin derivatives suggests that MAIT cells may have an important role in
first line of defense as part of the liver firewall. As such, MAIT cells are promising targets for modulating the host defense and
inflammation in both acute and chronic liver diseases.
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INTRODUCTION
Enteric commensals and pathogens are usually confined to the gut by
the intestinal epithelium and mesenteric lymph nodes, but in the
presence of intestinal inflammation and increased permeability, the
liver is the first organ to receive gut-derived bacteria and their
products. Thus, the liver functions as a second 'firewall', clearing
commensals from the portal circulation where intestinal defenses are
overwhelmed,1 and is enriched with a number of innate immune cells,
including Kupffer cells (liver-resident macrophages), natural killer
(NK) cells and innate-like T cells. In the human liver, mucosal-
associated invariant T cells (MAIT) cells are the most dominant
population of innate-like T cells, comprising up to 50% of all T cells in
the liver,2 which is in contrast to invariant NKT cells (iNKT; ~ 1%)
and γδ T cells (~15%).3,4
The invariant T-cell receptor (TCR) rearrangement of MAIT cells,
Vα7.2-Jα33, was first identified during an extensive analysis of the
TCR repertoire of human CD4−CD8− (double-negative; DN) T cells,
Porcelli et al.5 and subsequently shown to be characteristic of a
novel population restricted by the non-polymorphic and highly
evolutionarily conserved major histocompatibility complex (MHC)
class Ib molecule, MHC class I-related protein 1 (MR1).6,7 The relative
abundance of Vα7.2-Jα33 transcripts in human gut biopsies, as well as
the enrichment of homologous Vα19-Jα33 transcripts among
murine lamina propria lymphocytes compared with intraepithelial
lymphocytes or mesenteric lymph nodes,7 led to this population being
called MAIT cells. Importantly, these cells were found to be broadly
reactive to bacterial and yeast species,8,9 because of their ability to
recognize metabolic intermediates of the microbial riboflavin synthesis
pathway.10
Despite their name, in humans MAIT cells are most enriched in the
liver, constituting 20–50% of intrahepatic T cells.2,11 The dominance
of MAIT cells in the liver suggests that they have a major defensive
role in maintaining the liver firewall and in driving liver inflammation
in disease. In this article, we will discuss what is currently known
about MAIT cell biology, and explore what role MAIT cells may have
in maintaining liver homeostasis and in liver disease.
MAIT CELL BIOLOGY
MR1 and its ligand
MR1 is an antigen-presenting molecule first sequenced in 1995,12 and
in contrast to the highly polymorphic MHC class I molecules, it is
highly conserved among mammals,13,14 with the α1–α2 domains of
human and mouse MR1 being 89–90% identical.13,15 MR1 expression
is essential for the development of MAIT cells, which are absent in
MR1− /− mice.7
Two seminal papers in 2010 showed that MR1-restricted
MAIT cells could be activated by various species of bacteria and yeast,
and were critical for early protection against bacterial infections.8,9
These reports, together with the observation that MAIT cells are
absent in germ-free mice,7,8 suggested that MR1 presents a microbial
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ligand. The nature of the MR1 ligand was subsequently discovered by
Kjer-Nielsen et al.10 who showed that MR1 can present derivatives of
the highly conserved riboflavin and folic acid synthesis pathways.
MAIT cells are, therefore, activated by organisms possessing the
riboflavin synthesis pathway, including Mycobacteria, Enterobacter,
Pseudomonas, Salmonella and Candida species, but not those lacking
it (e.g. Streptococcus pyrogenes and Enterococcus faecalis).8,9 The most
potent MAIT cell activatory ligand found to date is 5-OP-RU
(5-(2-oxopropylideneamino)-6-D-ribitylaminouracil), generated from
the non-enzymic condensation of an early intermediate of the
riboflavin synthesis pathway with glyoxal or methylglyoxal
byproducts.16 Folate-based ligands such as 6-formylpterin and its
synthetic analog, acetyl-6-formylpterin, have also been shown to
inhibit conventional MAIT cell activity,17,18 but can activate
non-conventional, folate-reactive MAIT cells.19 MR1-tetramers loaded
with riboflavin and folate intermediates have subsequently allowed the
specific detection and characterization of human and murine
MAIT cells.16,19–21
The MR1 transcript is ubiquitously expressed,12,13 but endogenous
surface expression of MR1 has been difficult to detect.22,23 Recently,
however, it was demonstrated that MR1 accumulates in the endo-
plasmic reticulum in an incompletely folded form, and in the absence
of bound ligands only a few MR1 molecules traffic to the surface.24
Increased ligand availability leads to the association of MR1 with
β2-microglobulin and egress of the MR1–β2-microglobulin–ligand
complex,24 inducing rapid MR1 surface expression.17,24,25 MR1 surface
expression also increases with the nuclear factor-κB-dependent
activation of antigen-presenting cells.26 This contrasts with MHC
class II and CD1, which capture their exogenous ligands in endosomal
compartments and are highly expressed even in the absence of
infection.24
MAIT cell TCR
The MAIT cell TCR is semi-invariant and relatively evolutionarily
conserved within mammals.6,27 The majority of human MAIT cells
express the canonical TCRα chain, Vα7.2-Jα33, although Vα7.2-Jα12
or Vα7.2-Jα20 are also used by a minority of MAIT cells.20,28 These
TCRα chains are preferentially paired with Vβ2 or Vβ13.2 in
humans.20,28 In mice, MAIT cells express Vα19-Jα33 that is paired
with Vβ6 or Vβ8,6,20,28 although Vβ usage can be variable.6,20,29
Recently, human nonclassical MR1-restricted T cells that have a
diverse TCR repertoire and do not express the Vα7.2 TCR chain have
also been identified, which are preferentially activated by folate-based
ligands,19 analogous to type II NKT cells.
MAIT cell tissue distribution
MAIT cells are rare in lymphoid tissues,2,30 because of their lack of
CCR7 and CD62L expression, required for lymph node homing.2,31
Instead, MAIT cells preferentially home to peripheral tissues, mediated
by expression of chemokine receptors CCR6 and CXCR6, gut-homing
integrin-α4β7 and low levels of CCR9.2,7 Indeed, they are called
'mucosal-associated' because the Vα7.2-Jα33 transcript was enriched
in the human gut compared with skin tissues when they were initially
characterized.7 MR1-tetramer studies have since confirmed their
enrichment in the gut with different MAIT cell frequencies reported
at different anatomical locations within the gastrointestinal tract.
A higher frequency of MAIT cells are present in the jejunum
(~60% of CD4− T cells)20 compared with reported frequencies in
healthy ileum (1.5% of T cells),32 colon (10% of T cells)33,34 and
rectum (2% of T cells)35 (Figure 1). Importantly, MAIT cells are
further enriched within the liver (20–50% of T cells), as will be
discussed later.2,36,37 MAIT cells are also abundant in human
peripheral blood (1–10% of T cells)2 and the lungs (2–4% of
T cells).38 A lower frequency of MAIT cells is also present in the
endometrium and the cervix,39 and MAIT cell TCR transcripts have
been reported in tissues such as kidneys, prostate and ovaries.28
In contrast to humans, MAIT cells are rare in commonly used
laboratory strains of mice,6,40 with the exception of the CAST/EiJ
strain,41 and, therefore, the majority of murine studies have used
invariant Vα19-Jα33 TCR transgenic (Vα19i-transgenic) mice.40 MR1
tetramers have allowed characterization of wild-type murine
MAIT cells, however, showing that in C57BL/6 mice, for example,
there is an enrichment of MAIT cells in the lung (mean 3.3% of
T cells), liver (0.6% of T cells) and lamina propria (0.7% of T cells).21
Liver 20-50%
Ileum 1.5%
Jejunum 
~60% of
CD4-T cells
Rectum 2%
Spleen <1%
Colon 10%
Peripheral Blood 1-10%
Liver:
B6: 0.6%
BALB/c: 0.4%
Spleen:
B6: 0.08%
BALB/c: 0.04%
Thymus:
B6: 0.05%
BALB/c: 0.02%
Lamina Propria:
B6: 0.7%
BALB/c: n/tLung:
B6: 3.3%
BALB/c: 0.2
Lymph node:
B6: 0.2%
BALB/c: 0.01%
Lung 2-4%
Figure 1 Distribution of human and murine MAIT cells in tissues. The
frequency of MAIT cells (defined either by MR1 tetramers or as CD161++
Vα7.2+ T cells) within T cells, as has been described in the indicated
tissues of mice and humans. MAIT cells are enriched within peripheral
organs including the liver and gut, whereas they are less enriched within
lymphoid organs. However, MAIT cells are much more abundant in humans
compared with common laboratory strains of mice.
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Interestingly, the frequency of MAIT cells in the tissues of wild-type
mice has been shown to markedly increase upon infection with
Francisella tularensis live-vaccine strain,42 Salmonella Typhimurium or
intranasal administration of 5-OP-RU in the presence of a toll-like
receptor (TLR) agonist.43
MAIT cell phenotype and effector functions
In addition to their distinct chemokine receptor profile, human
MAIT cells have a characteristic phenotype that has been described
in detail (Figure 2). In adults, MAIT cells express a uniform effector
memory phenotype.2,31 Although cord blood MAIT cells are naïve,
they share a preprogrammed transcriptional signature with adult
MAIT cells,44 in line with the acquisition of their innate reactivity
and activated phenotype during development.30 In humans the
majority of MAIT cells are CD8+, with a small fraction of DN cells,
as well as a very minor population that express the CD4 coreceptor.20
Interestingly, more than half of CD8+ MAIT cells express the
homodimer CD8αα, with a smaller frequency of cells expressing the
CD8αβ heterodimer. This is unique to MAIT cells, as conventional
CD8+ T cells express the CD8αβ coreceptor,20,44 and is acquired early
in development.30
Another key feature of human MAIT cells is the high expression of
the C-type lectin-like receptor, CD161, and in the steady state, CD161
++Vα7.2+ T cells have been shown to overlap with the cells stained by
the MR1 tetramer.20,45 Furthermore, CD161 is one of the earliest
markers to be expressed on MAIT cells, already high in the thymus
and fetal organs,30 as well as in the cord blood.2,44,46 MAIT cells also
express high levels of interleukin-18R (IL-18R), enabling them to
rapidly release interferon-γ (IFNγ)11,47 and tumor necrosis factor-α
(TNFα) (unpublished observations) in response to innate cytokines
such as IL-12 and IL-18. This is further confirmed by the activation of
MAIT cells by E. faecalis, which lacks the riboflavin synthesis pathway,
and TLR agonists, in an IL-12- and IL-18-dependent manner.11,47
In line with this, control of intracellular M. bovis bacillus
Calmette-Guérin (BCG) growth in vitro by murine MAIT cells
required IL-12, but was independent of MR1 signaling.48 This ability
to be activated by cytokines alone is shared with other innate T cells,49
as conventional T cells require TCR signaling before the expression of
cytokine receptors such as IL-18R,50 and is attributable to the
expression of promyelocytic leukemia zinc-finger by these cells.21,51
In addition to IFNγ and TNFα, which can be induced both in a
TCR-dependent and -independent manner,2,9,47 MAIT cells have a
constitutively high expression of RAR-related orphan receptor γt and
the associated ability to express IL-17A,2,31,44 and constitute the main
IL-17-producing T-cell population within the human liver.36 Although
rapid IL-4, IL-5 and IL-10 expression has been described in
MAIT cells from Vα19i-transgenic mice,40 the expression of these
cytokines from human MAIT cells ranges from none2,36,52 to low.28,53
Interestingly, however, IL-10 expression from MAIT cells is
particularly high in adipose tissue,54 suggesting an immunosuppressive
function for MAIT cells in certain tissues.
The effector functions of MAIT cells also includes their ability to
degranulate and kill bacterially infected or sensitized cells, lysing cells
infected with BCG28 and Shigella.55 Ex vivo resting MAIT cells are not
efficient killers because of their lack of granzyme B (GrB) and low
levels of perforin expression compared with conventional CD8+
T cells.56 Upon activation, either in an MR1-dependent manner or
longer cultures with inflammatory cytokines, however, they upregulate
GrB and perforin, greatly enhancing killing of target cells.2,56–58 GrB
may therefore be a useful activation marker of MAIT cells.
Finally, despite expansion of MAIT cells after birth,2,46 adult
MAIT cells lack expression of Ki67 in the periphery2 and were initially
thought to be poorly proliferative.2,8,40 However, recent studies have
confirmed the ability of murine and human MAIT cells to proliferate
CD45RO
CD8CD161++
IL-18R
IL-12R
CCR2
CCR5
CCR6
CXCR6
PLZF+
RORγt+
T-bet+ TCR
(Vα7.2-Jα33)
MR1
IFNγ
TNFα
IL-17
TLR
ER
CD26
PerforinGranzyme B
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synthesising
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Figure 2 The phenotype of human MAIT cells and their mechanisms of activation. Mature MAIT cells in peripheral blood express the chemokine receptors
CCR2, CCR5, CCR6, CXCR6, the C-type lectin-like receptor CD161, the dipeptidase CD26 and a CD45RO+CCR7− effector memory phenotype, with the
majority of human MAIT cells expressing the CD8 coreceptor. MAIT cells also express the transcription factors RAR-related orphan receptor γt (RORγt), T-bet
and promyelocytic leukemia zinc-finger (PLZF) at rest. During bacterial infection, derivatives of the riboflavin biosynthesis pathway are captured by MR1 and
presented on the surface of antigen-presenting cells (APCs). Alternatively, viruses can also rapidly activate MAIT cells in an MR1-independent manner owing
to the induction of IL-18, IL-12 and IFNα. Activated MAIT cells express IFNγ, TNFα, granzyme B, perforin and IL-17.
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in both an MR1-dependent manner and in response to cytokines
in vitro21,56,59 and in vivo.42 As MAIT cells are highly sensitive to
activation-induced cell death,60 one possible explanation for the
discrepancy between studies may be that overstimulation of
MAIT cells in some studies led to the loss of MAIT cells before they
were able to proliferate.
MAIT CELLS AND DISEASE
MAIT cells in bacterial infections
High evolutionary conservation of MR1 and its recognition of
intermediates of the riboflavin pathway, conserved in various species
of bacteria and yeast, suggests that MAIT cells have a critical and non-
redundant role in microbial protection. Indeed, a number of papers
have suggested that MAIT cells have a protective role in bacterial
infections. MR1− /− mice lacking MAIT cells had a higher bacterial
burden in the first few days following intraperitoneal injection of
Escherichia coli or intravenous injection of Mycobacterium abscessus,8
and were overwhelmed by a fatal burden of intraperitonially injected
Klebsiella pneumonia.61 Aerosol infection models have demonstrated
MAIT cells to be essential for early control of bacterial burden in the
lung.42,48 Interestingly, mice were protected from F. tularensis
live-vaccine strain even in the absence of conventional αβ T cells,
but were overcome in MR1− /− mice,42 suggesting that MAIT cells may
be important for microbial control in immunocompromised patients.
Various studies of MAIT cell frequencies in patients indicate
involvement in bacterial infections. For example, there is a higher
frequency of MAIT cells in the lung of patients with Mycobacterium
tuberculosis infection, with lower frequencies of MAIT cells in the
blood.8,9 Reduced MAIT cell frequencies are, however, only observed
in patients with active M. tuberculosis infection, but not latent
infection,9 suggesting MAIT cells are recruited to the lung in active
disease. Peripheral MAIT cells in these patients also have increased
expression of the exhaustion marker, programmed cell death protein
1,62,63 and their responsiveness to M. bovis BCG is increased upon
programmed cell death protein 1 blockade62 (Table 1).
In addition to pulmonary infections, there is evidence of MAIT cell
involvement in enteric infections, as MAIT cells are reduced early in
the blood of patients that received an attenuated strain of Shigella
dysenteriae 1,55 as well as in Vibrio cholera O1-infected children.64
Interestingly, the presence of activated MAIT cells in the periphery
was specific to vaccine responders that developed an
SD1-lipopolysaccharide-specific immunoglobulin (Ig) A response,55
and correlated with protective Vibrio cholera O1-lipopolysaccharide-
specific immunoglobulin A and immunoglobulin G antibody
responses.64 These two studies suggest that MAIT cells have a role
in the development of protective antibody responses against
polysaccharide antigens.
Last, reduced MAIT cell frequencies have been associated with
increased severity of cystic fibrosis, and is particularly enhanced in
patients with chronic Pseudomonas aeruginosa infections,65 as well as
being a risk factor in critically ill patients with sepsis for subsequent
nosocomial infections.66
MAIT cells in viral infections
Although early studies showed MR1− /− mice were not susceptible to
influenza compared with control mice,8 MAIT cell frequencies are
markedly affected during human viral infections. For example,
MAIT cells have been consistently and repeatedly reported to be
severely depleted from the periphery of patients infected with human
immunodeficiency virus (HIV),33,35,63,67–69 as well as HIV/M.
tuberculosis-co-infected patients.70 MAIT cell loss occurs as early as
2–3 weeks after HIV infection,70 and does not recover with successful
antiretroviral therapy.33,35 CD8+ MAIT cells in the rectal mucosa35 and
colon33 were better preserved, although CD4+ MAIT cells were
specifically lost from the rectal mucosa, in line with the significant
loss of all CD4+ T cells in the rectal mucosa in HIV-infected patients.35
As peripheral CD8+ MAIT cells were not specifically infected by HIV,33
depletion of MAIT cells from the blood of HIV-infected patients is
suggested to be due to either the activation-induced cell death of
MAIT cells from HIV-induced microbial translocation into the
periphery33 or exhaustion and downregulation of the MAIT cell
marker CD161.35 Although a recent tetramer study confirmed the loss
of MAIT cells from the peripheral blood of HIV-infected patients, with
no detectable loss of CD161 expression on MAIT cells,67 the mechan-
ism behind the severe depletion of MAIT cells in these patients remains
to be explained. Nevertheless, the loss of MAIT cells may potentially
have a profound effect on microbial protection in HIV-infected
patients, as exemplified by the loss of mucosal T-helper type 17 cells
in simian immunodeficiency virus-infected rhesus macaques.71
In addition to HIV, a loss of MAIT cells from the periphery has also
been observed in patients with dengue and severe influenza
infection,72 as well as in chronic hepatitis C virus (HCV)
patients,72,73 as discussed in detail later. In vivo MAIT cell activation
was demonstrated in these patients, and correlated with disease
severity in acute dengue. Activation of MAIT cells by the different
viruses was dependent on IL-18 in synergy with IL-12, IL-15 and/or
IFN-α/β, in line with previous studies showing that IL-12 in
combination with IL-18, secreted by monocytes through TLR stimula-
tion, can activate MAIT cells in vitro.11,47 These studies suggest that
MAIT cells may have a larger role in the immune system that is not
limited to protection against bacterial infection.
MAIT cells and autoimmunity
There is increasing interest in the involvement of MAIT cells in
autoimmune conditions, which has been reviewed in detail
elsewhere.74 In particular relevance to the liver, however, a number
of studies have linked MAIT cells with intestinal inflammation. For
instance, reduced frequencies of MAIT cells have been consistently
demonstrated in the blood of patients with inflammatory bowel
disease (both Crohn’s disease and ulcerative colitis),32,75–77 although
there are conflicting findings between studies in the frequency of
MAIT cells within the inflamed tissues.32,75,76 MAIT cell frequencies
are also altered in coeliac disease, where MAIT cells are depleted from
the blood and gut.78 Although the fate of MAIT cells in the tissue
during intestinal inflammation requires further investigation, it is
possible that chronic inflammation of the gut leads to both the
recruitment and accumulation of MAIT cells, followed by their
activation-induced cell death because of bacterial translocation
and dysbiosis. In addition to intestinal inflammatory conditions,
MAIT cells may also have a role in arthritic diseases, as they have
been shown to exacerbate collagen-induced arthritis,79 whereas
depletion of blood MAIT cells has also been reported in patients with
systemic lupus erythromatosis and rheumatoid arthritis.31,53 Various
reports have also associated MAIT cells with multiple sclerosis, with
the presence of MAIT cells in multiple sclerosis lesions confirmed
by immunohistochemistry,77,80,81 although both regulatory and
pathogenic roles have been implicated.80,82
MAIT cells and cancer
Little is known about the role of MAIT cells in cancer. An early
study reported the increased detection of Vα7.2-Jα33 transcripts in
kidney cancer tissue and brain tumors compared with control tissue
MAIT cells and the liver
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and peripheral blood samples.83 Recent studies in colonic
adenocarcinoma84 and colorectal cancer patients85 have supported
these findings, demonstrating highly activated MAIT cell accumulation
in tumor tissue, with the degree of MAIT cell infiltration into
colorectal tumors negatively correlating with life expectancy.86 As
MAIT cells can secrete both IFNγ—which can promote tumor-specific
T-cell responses, as well as IL-17—which leads to the expansion and
accumulation of immunosuppressive neutrophils and myeloid-derived
suppressor cells,87–89 the role of MAIT cells in tumor development
may depend on the tumor microenvironment and the ratio between
IL-7
IFNα/β
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Figure 3 Proposed role of MAIT cells in the liver. (a) In the steady-state liver, MAIT cells home to the bile ducts within the portal tract through their
expression of the chemokine receptors CXCR6 and CCR6 where they are located both adjacent to the biliary epithelium and within hepatic sinusoids. This
allows them to protect against infection via the biliary tree and from the portal and systemic circulation via the portal vein and hepatic artery. (b) In the event
of ascending biliary infection and following bacterial breech of the biliary epithelium, liver MAIT cells are recruited through their upregulation of CXCR3 and
increased expression of chemokines (CCL20) and adhesion molecules (intercellular adhesion molecule 1 and vascular cell adhesion molecule 1) in the liver.
MAIT cells are activated by riboflavin metabolites presented by MR1 expressed on both professional (Kupffer cells) and non-professional (BECs) antigen-
presenting cells. MR1-activated MAIT cells release CD40L, which induces the expression of Fas, as well as cytotoxic molecules Granzyme B and perforin,
leading to apoptosis of BECs. MAIT cells also express the proinflammatory cytokines IFNγ and TNFα, which activates Kupffer cells, BECs, liver sinusoidal
endothelial cells (LSECs) and dendritic cells (DCs), whereas IL-7 produced by inflamed hepatocytes also promote IL-17 production from MAIT cells, leading
to further inflammation and activation of Kupffer cells, BECs and hepatic stellate cells (HSCs). MAIT cells also produce IFNγ in response to IL-12 and IL-18,
secreted by sinusoidal Kupffer cells activated by TLR4 (bacterial LPS) and TLR8 (viral ssRNA) agonists, leading to viral and bacterial control DCs.
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IFNγ- and IL-17-secreting cells. Further studies into the role of
MAIT cells in cancer and their immunomodulatory potential,
as has been demonstrated with iNKT cells,90 could have important
implications for cancer immunotherapy.
Last, it is important to note that the precise physiological role of
MAIT cells in most of these conditions (bacterial, viral, autoimmune
or cancerous) remains to be defined, with the majority of studies
focusing on their frequency within the peripheral circulation and
tissue, whether they contribute to disease or have a protective role in
humans remains unclear.
MAIT CELLS IN THE LIVER
Role of MAIT cells in the liver
Mouse models have demonstrated that in the presence of healthy
intestinal mucosa, the liver remains a sterile organ,1 with the
mesenteric lymphoid system containing the immune response to
commensal gut organisms.91 Yet, the liver provides an important
second ‘firewall’ where intestinal mucosal defenses are breached or in
the presence of systemic infection.1 The liver hosts not only the large
phagocytic Kupffer cell population, dendritic cells, liver sinusoidal
epithelial cells and hepatic stellate cells but also rapidly activated innate
cells such as NK, iNKT and MAIT populations.92 The innate reactivity
of MAIT cells to both MR1-presented bacterially derived metabolites
of riboflavin and proinflammatory cytokines including IL-12, IL-18
and type I IFN indicates that MAIT cells are well placed to have an
important role in first line of defense as part of the liver firewall. With
little data published to date, we are only just beginning to understand
their significance within this complex immunological organ.
MAIT cells are highly enriched in the human liver, representing
20–50% of intrahepatic T cells, compared with the gut.2,36 This is in
keeping with their homing receptor expression profile, and although
MAIT cells express the gut-homing integrin-α4β7,7 they express lower
levels of the gut-homing chemokine receptor CCR9 compared with
other T cells.2,37 Instead, MAIT cells express receptors that allow them
to home to the liver, such as CXCR6 and CCR6, which binds CXCL16
and CCL20, respectively—chemokines constitutively expressed in the
liver.93,94 This liver-homing phenotype is conserved in mice, as murine
MAIT cells also express CXCR6,21 similar to the murine hepatic iNKT
cell population.95 CCL20 is also upregulated in the inflamed liver and
drives CCR6+ T-cell localization to the biliary epithelium.96 Indeed,
recent work by Jeffery et al.37 has described Vα7.2+ and Vα7.2+CD161+
cells to predominantly reside around bile ducts within the portal tracts
in both healthy and diseased livers. Importantly, bacterially loaded
biliary epithelial cells (BECs) were able to activate MAIT cells in an
MR1-dependent manner, and suggests a mechanism by which
MAIT cells may defend the biliary mucosa against ascending infection
from the gut. In the inflamed liver, MAIT cells may be further
recruited to the sinusoids through their expression of CXCR3, LFA-1
and VLA-4,37 as IFNγ-inducible CXCR3 ligands, intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1, have all been shown
to mediate recruitment of lymphocytes during inflammation.97 The
distribution of intrahepatic MAIT cells is likely critical to under-
standing their function within the liver.
Three features of MAIT cells in the context of liver immunosur-
veillance are important to note. First, although at a transcriptional level,
intrahepatic MAIT cells are very similar to their blood counterparts,
liver MAIT cells are highly activated and almost all express the
activation marker CD69, as well as HLA-DR and CD38.36,37 This
suggests that liver MAIT cells are in a highly activated state, poised to
respond to incoming antigen from the gut. Second, intrahepatic
MAIT cells, along with CD56bright NK cells, are the main source of
IFNγ after TLR8 stimulation of liver-derived mononuclear cells, medi-
ated by their ability to respond to IL-12 and IL-18 from monocytes.11
The striking sensitivity of intrasinusoidal cells in this study to the TLR8
agonist ssRNA40, compared with other TLR agonists, suggests that
intrahepatic cells are highly reactive to viral and phagocytosed bacterial
RNA,98 and that MAIT cells are an important effector population in
the liver. Third, MAIT cells are the predominant IL-17 producers
among intrahepatic T cells (~65% of IL-17+ T cells) following phorbol
12-myristate 13-acetate/ionomycin stimulation.36 As IL-17 targets
multiple cell types in the liver, including Kupffer cells and BECs, to
produce proinflammatory cytokines and chemokines,99 MAIT cells
may be important regulators of hepatic inflammation and fibrosis.
Interestingly, however, liver MAIT cells in the steady state are
unable to produce IL-17 upon TCR stimulation.36 Indeed, MAIT cells
from the liver appear less skewed towards type 17 functions (IL-17 and
IL-22 production) compared with those of the mucosa. For example,
MAIT cells of the fetal liver failed to produce IL-22 on MR1-
dependent stimulation, in contrast to those of the small intestine.30
Similarly, MAIT cells derived from the female genital tract were able to
produce IL-17 and IL-22 on bacterial stimulation.39 The presence of
commensal bacteria at mucosal surfaces may drive type 17 skewing of
mucosal MAIT cells through IL-1β production by resident
macrophages.100 In the steady state, MAIT cells seem to require IL-7
licensing before acquiring the ability to secrete IL-17 in response to
TCR stimulation, potentially by increasing their sensitivity to
TCR-mediated signals,36,57 but liver MAIT cells may become similarly
skewed to mucosal MAIT cells during episodes of infection.
Taken together these studies suggest hepatic MAIT cells are highly
activated within the liver and likely have a defensive role against a
range of extra- and intracellular bacteria, fungi and viruses through
their abundant and rapid production of IFNγ and IL-17 (Figure 3).
MAIT CELLS AND LIVER DISEASE
Inflammatory liver diseases
In the most comprehensive study to date of MAIT cells in liver disease,
Jeffery et al.37 describe the distribution, function and phenotype of
hepatic MAIT cells from healthy controls and explants from patients
with acute non-A, non-B hepatitis, as well as the end-stage
chronic liver diseases such as autoimmune hepatitis, primary biliary
cholangitis, primary sclerosing cholangitis, alcoholic liver disease and
non-alcoholic steatohepatitis (NASH).37 Overall, a reduction in
MAIT cells was seen in patient blood and livers compared with
controls, in agreement with another study of end-stage liver disease.11
The similar distribution of Vα7.2+ cells and CD161+Vα7.2+ cells
around the bile duct in both controls and the chronic diseases studied
would suggest that the presence of these cells is likely more
physiological than pathological in this location (or related to
end-stage liver disease). Although the specificity of these cells needs
to be confirmed, peribiliary MAIT cells may provide defense against
ascending infection via the biliary system, as discussed above.
However, as ligation of CD40 on BECs leads to their Fas-dependent
apoptosis,101 upregulation of CD40L on MAIT cells in response to
bacteria-derived MR1 ligands presented by BECs suggests that
MAIT cells could potentially drive bile duct damage, contributing to
pathogenesis in biliary disease.
Hepatitis C infection
Two recent papers have clearly demonstrated that circulating
MAIT cells in chronic HCV patients are reduced in frequency.72,73
This supports previous observations that blood CD161++CD8 T cells,
the majority of which are MAIT cells in adults,2 are significantly
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reduced in patients with chronic HCV.44 Whether this represents
blood-to-tissue translocation or activation-induced cell death, as has
been suggested in HIV infection,33 has not been addressed. Ex vivo
analysis of MAIT cells from patients with chronic HCV showed that
activation markers such as GrB, CD38 and CD69 were
upregulated,72,73 and MAIT cells could be activated upon in vitro
coculture with HCV-exposed antigen-presenting cell.72 Additionally,
type I IFNs, known to have an important role in viral control, were
shown to induce MAIT cell production of IFNγ in combination with
IL-12 or IL-18, and where antigen-presenting cells infected with HCV
were cocultured with a vaccine virus-derived soluble type 1 IFN
receptor (B18R), MAIT cell activation was inhibited. Interestingly, in
an HCV Sofosbuvir treatment trial, those patients in the arm receiving
pegylated-IFN, in addition to Sofosbuvir and ribavirin, had a higher
sustained virologic response rate, as well as activated circulating
MAIT cells compared with the other treatment arms. Whether this
indicates a direct role for MAIT cells in HCV control and clearance or
whether they are simple bystanders requires further investigation.
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease, affecting up to 40% of western adult
populations,102,103 encompasses a spectrum of disorders ranging from
isolated, benign hepatic steatosis to progressive NASH. Closely linked
to the metabolic syndrome, non-alcoholic fatty liver disease has a
prevalence of 70% among type 2 diabetic patients and 90% among the
morbidly obese.104 The pathogenesis of NASH is much debated,104
and likely the result of a number of complex factors including insulin
resistance and disrupted lipid metabolism; lipotoxicity and hepatocyte
death; altered intestinal barrier function, gut dysbiosis and bacterial
overgrowth; altered systemic adipokines/cytokines and host genetics.
A direct role of MAIT cells in NASH has not been studied, but, in the
context of altered gut barrier function, dysbiosis of the microbiome
and bacterial overgrowth, described as part of the metabolic syn-
drome, will be an important area to explore. However, a recent study
of MAIT cells in obese and type 2 diabetic patients demonstrated a
marked reduction in circulating MAIT cells in both patient groups
compared with controls.45 In this study, the residual circulating
population expressed the activation markers CD69 and CD25, with
enhanced functionality and proinflammatory cytokine production
upon mitogen stimulation. Furthermore, MAIT cells were enriched
in the adipose tissues compared with the peripheral blood of obese
patients, where they were potent and predominant producers of IL-17,
with up to 90% of adipose tissue MAIT cells capable of secreting
IL-17. Circulating MAIT cell numbers was restored at 3 months
following bariatric surgery, whereas they returned to normal function
6 months after surgery. Increased IL-17 from peripheral blood
MAIT cells has also been observed in obese children.54 Changes to
the gut microbiome and intestinal permeability that occur in obesity
and type 2 diabetic may lead to the accumulation of MAIT-activating
microbial products within adipose tissue and account for the
activation state and enhanced function of MAIT cells observed.
Indeed, IL-7, known to license MAIT cell function,36,57 is oversecreted
by stromal vascular cells from the omental adipose tissue of obese
patients.105 This may explain the enhanced functionality of MAIT cells
in this setting where they likely are important drivers of inflammation
and thus of the pathogenic chain of insulin resistance, lipolysis, high
circulating free fatty acids and hepatic fat accumulation in the
development of non-alcoholic fatty liver disease/NASH. However,
the onset of diabetes was delayed in non-obese diabetic Vα19i-
transgenic mice compared with non-transgenic mice, suggesting that
they may also have a suppressive role that is altered in disease.106
CONCLUSION
MAIT cells are emerging as significant players in the human immune
system where they represent a major lymphocyte population—this is
most obvious in the liver where their dominance, indeed even their
presence, has only been evident in the past few years. Our under-
standing of the distinct biology of MAIT cells is rapidly increasing as
the field widens and appears to include not only responsiveness to
bacteria but also to inflammatory and viral signals. Their enrichment
within the liver is striking and there is much work to be carried out in
understanding the physiologic role of MAIT cells, as guardians of the
biliary mucosa, as monitors of sinusoidal hygiene and as part of the
liver’s defensive firewall. Loss of MAIT cells in fibrotic liver disease, as
has been indicated, may lead to weakening of this firewall and
increased susceptibility to systemic infections—it may be possible to
address this mechanistically in emerging mouse models. Their role in
the pathogenesis of liver disease also needs to be defined—clearly they
are present at the site of inflammation, but to what extent they are
protagonists, protectors or just innocent bystanders again may only be
solved by analysis using appropriate mechanistic in vivo models. Even
with these, given the specific and chronic nature of some of the
infectious/inflammatory processes, further clinical correlative and
mechanistic studies are needed.
Overall, given their distinctive functions and surface phenotype,
MAIT cells represent attractive therapeutic targets to modulate host
defense and inflammation in the liver and other organs, and certainly
excellent markers of responses to biologic therapies. Both avenues—
therapeutic and diagnostic—are ripe for exploitation in the future.
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